Radiosurgery Or Fractionated Stereotactic Radiotherapy Plus Whole-Brain Radioherapy in Brain Oligometastases: a Long-Term Analysis
ANTICANCER RESEARCH 35: 3055-3060 (2015) Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole-brain Radioherapy in Brain Oligometastases: A Long-term Analysis MARIO BALDUCCI1, ROSA AUTORINO1, SILVIA CHIESA1, GIANCARLO MATTIUCCI1, ANGELO POMPUCCI2, LUIGI AZARIO3, GIUSEPPE ROBERTO D’AGOSTINO1, MILENA FERRO1, ALBA FIORENTINO1, SERGIO FERSINO1, CIRO MAZZARELLA1, CESARE COLOSIMO4, VINCENZO FRASCINO1, CARMELO ANILE2 and VINCENZO VALENTINI1 Departments of 1Radiation Oncology, 2Neurosurgery, 3Physics and 4Radiology, Catholic University of the Sacred Heart, Rome, Italy Abstract. Aim: To analyze the outcome of patients with number, size, location, the patient’s Karnofsky performance brain oligometastases treated by radiosurgery (SRS) or status (KPS), age, extent of systematic disease and primary fractionated stereotactic radiotherapy (FSRT) after whole- disease status (4, 5). brain radiotherapy (WBRT). Patients and Methods: Overall Patients with one or two brain metastases and with survival (OS) and local control (LC) were evaluated in favorable prognostic features have a relatively favorable patients (patients) with 1-2 brain metastases. Results: Forty- survival; thus, the treatment is frequently more aggressive seven patients were selected. They were submitted to WBRT than for patients with multiple brain metastases (5). (median dose=3,750 cGy) followed by SRS (17 patients; Radiosurgery (SRS) delivered as a single fraction to median dose=1,500 cGy) or FSRT (30 patients; median individual intracranial lesions has been the most common dose=2,000 cGy). Median follow-up was 102 months technique used to dose-escalate on lesions following whole (range=17-151); the median survival was 22 months for the brain radiotherapy (WBRT) and considered as safe SRS group and 16 months for the FSRT group.
[Show full text]